TAFAZZIN Chromosome X

Tafazzin, phospholipid-lysophospholipid transacylase
109 variants 109 Health Risk

Upload your DNA to see your personal genotypes for variants in TAFAZZIN.

What This Gene Does
This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq, Jul 2008]
Associated Conditions (11)
Primary dilated cardiomyopathy
3-Methylglutaconic aciduria type 2
Endocardial fibroelastosis
Cardiovascular phenotype
TAFAZZIN-related disorder
Cardiomyopathy
Primary familial hypertrophic cardiomyopathy
Thyroid cancer
nonmedullary
1
Left ventricular noncompaction cardiomyopathy
Key Variants
RS1057515818
Conflicting classifications of pathogenicity
Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis
Health Risk
RS1223065368
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
Health Risk
RS1298362744
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS1557194488
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS200405157
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
Health Risk
RS200909606
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis, Primary dilated cardiomyopathy
Health Risk
RS2522937677
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS2522986801
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder, 3-Methylglutaconic aciduria type 2
Health Risk
RS374146054
Conflicting classifications of pathogenicity
Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype
Health Risk
RS397515739
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS397515741
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS397515742
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
All Variants (109)
RSID Category Clinical Significance Conditions
RS1057515818 Health Risk Conflicting classifications of pathogenicity Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis
RS1223065368 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
RS1298362744 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS1557194488 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS200405157 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
RS200909606 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis, Primary dilated cardiomyopathy
RS2522937677 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS2522986801 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder, 3-Methylglutaconic aciduria type 2
RS374146054 Health Risk Conflicting classifications of pathogenicity Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype
RS397515739 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS397515741 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS397515742 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS397515745 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS397515746 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS397515750 Health Risk Conflicting classifications of pathogenicity Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2, Primary dilated cardiomyopathy
RS62617809 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS727504327 Health Risk Conflicting classifications of pathogenicity Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2, Primary dilated cardiomyopathy
RS781986219 Health Risk Conflicting classifications of pathogenicity Endocardial fibroelastosis, 3-Methylglutaconic aciduria type 2, Primary dilated cardiomyopathy
RS782099193 Health Risk Conflicting classifications of pathogenicity Cardiomyopathy, 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS782195445 Health Risk Conflicting classifications of pathogenicity Cardiomyopathy, 3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder
RS782240044 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS782404246 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
RS782470471 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
RS782564325 Health Risk Conflicting classifications of pathogenicity Endocardial fibroelastosis, Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2
RS782653725 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, Cardiomyopathy, 3-Methylglutaconic aciduria type 2
RS782731479 Health Risk Conflicting classifications of pathogenicity Primary familial hypertrophic cardiomyopathy, 3-Methylglutaconic aciduria type 2, Primary familial hypertrophic cardiomyopathy
RS794729173 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS876661112 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS990648341 Health Risk Conflicting classifications of pathogenicity 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, Thyroid cancer
RS104894942 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS1057518416 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, Thyroid cancer, nonmedullary
RS1060500044 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS1557191139 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS1557194377 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS1557194525 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS1603376560 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS1603376938 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS1603377936 Health Risk Likely pathogenic Left ventricular noncompaction cardiomyopathy, Left ventricular noncompaction cardiomyopathy
RS1603377945 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
RS1603382251 Health Risk Likely pathogenic
RS2068331233 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS2068570435 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS2068574381 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS2068606445 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS2148186695 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS2148194576 Health Risk Likely pathogenic
RS2522919648 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS2522923651 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS2522924351 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
RS2522924439 Health Risk Likely pathogenic 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
1 2 3 Next »
Sign Up to Analyze Your DNA Log In